Peginterferon alfacon-1
Identification
- Generic Name
- Peginterferon alfacon-1
- DrugBank Accession Number
- DB05860
- Background
PEGylation is a technology for the chemical attachment of polyethylene glycol (PEG) polymer chains to a broad range of drug substances such as peptides and proteins including antibody fragments; small molecules, and other drugs. [Infergen] is a bio-engineered type I interferon alpha that is FDA-approved for the treatment of patients with chronic hepatitis C infections.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Interferons - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- PEG INF alfacon-1
- PEG-Alfacon
- PEG-Infergen
- PEG-interferon alfacon-1
- Pegylated interferon alfacon-1
Pharmacology
- Indication
Investigated for use/treatment in hepatitis (viral, C).
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
The effect of PEGylation is to increase drug circulation time in the bloodstream, improve drug solubility and stability, and reduce immunogenicity. The potential advantages of PEGylation are to decrease dosing frequency, improve drug efficacy and safety, improve stability, and simplify drug formulation.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAntihemophilic factor (recombinant), PEGylated The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Peginterferon alfacon-1. Certolizumab pegol The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Peginterferon alfacon-1. Damoctocog alfa pegol The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Peginterferon alfacon-1. Elapegademase The therapeutic efficacy of Elapegademase can be decreased when used in combination with Peginterferon alfacon-1. Lipegfilgrastim The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Peginterferon alfacon-1. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Witthoeft T, Fuchs M, Ludwig D: Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study. World J Gastroenterol. 2007 Jan 28;13(4):579-84. [Article]
- Higuchi Y, Hashida M: [Pharmaceutical device of IFN]. Nihon Rinsho. 2006 Jul;64(7):1374-9. [Article]
- Wang F, Liu Y, Li J, Ma G, Su Z: On-column refolding of consensus interferon at high concentration with guanidine-hydrochloride and polyethylene glycol gradients. J Chromatogr A. 2006 May 19;1115(1-2):72-80. Epub 2006 Mar 20. [Article]
- External Links
- PubChem Substance
- 347910276
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Drug created at November 18, 2007 18:28 / Updated at June 12, 2020 16:52